MAM
NERV icon

Meeder Asset Management’s Minerva Neurosciences NERV Stock Holding History

Meeder Asset Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-129
Closed -$5K – 2311
2020
Q1 		$5K Buy
129
+15
+13% +$905 ﹤0.01% 1791
2019
Q4 		$6K Sell
114
-1,462
-93% -$64.5K ﹤0.01% 1726
2019
Q3 		$98K Buy
1,576
+1,396
+776% +$79.1K 0.01% 809
2019
Q2 		$8K Buy
180
+94
+109% +$4.71K ﹤0.01% 1527
2019
Q1 		$5K Sell
86
-1,522
-95% -$91.5K ﹤0.01% 1398
2018
Q4 		$86K Buy
1,608
+758
+89% +$55.5K 0.01% 677
2018
Q3 		$85K Buy
850
+614
+260% +$46.1K 0.01% 681
2018
Q2 		$15.5K Buy
236
+171
+263% +$10.4K ﹤0.01% 1030
2018
Q1 		$3K Sell
65
-6
-8% -$288 ﹤0.01% 1325
2017
Q4 		$4K Buy
71
+11
+18% +$545 ﹤0.01% 1369
2017
Q3 		$4K Hold
60
– – ﹤0.01% 1324
2017
Q2 		$4K Sell
60
-81
-57% -$5.24K ﹤0.01% 1262
2017
Q1 		$9K Buy
+141
New +$10.9K ﹤0.01% 878

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meeder Asset Management's NERV Position: Q2 2020 in Review

Meeder Asset Management sold out of Minerva Neurosciences (NERV) in Q2 2020, closing a stake of 129 shares — an estimated $5K sold.

Meeder Asset Management first reported a position in NERV in Q1 2017 and held it in 13 quarters. The position peaked at $98K in Q3 2019. 80 funds tracked by Wall St. Rank hold NERV as of Q2 2020.

  • Meeder Asset Management reported no remaining Minerva Neurosciences position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 129 Minerva Neurosciences shares in Q2 2020, an estimated $5K.
  • Meeder Asset Management first reported a position in Minerva Neurosciences in Q1 2017 and held it in 13 quarters.
  • Meeder Asset Management's Minerva Neurosciences position peaked at $98K in Q3 2019.
  • 80 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.